Crystalline rosuvastatin intermediate

Details Crystalline rosuvastatin intermediate Crystalline rosuvastatin intermediate

2011-01-11

2011-01-11

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

Reexamination Certificate

active

07868169

ABSTRACT:
Provided is a crystalline rosuvastatin intermediate and processes for preparation thereof.

REFERENCES:
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4739073 (1988-04-01), Kathawala
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5354879 (1994-10-01), Konoike et al.
patent: RE37314 (2001-08-01), Hirai et al.
patent: 6316460 (2001-11-01), Creekmore et al.
patent: 6333198 (2001-12-01), Edmeades et al.
patent: 6777552 (2004-08-01), Niddam-Hildesheim et al.
patent: 6858618 (2005-02-01), Raza et al.
patent: 2004/0009997 (2004-01-01), Taylor et al.
patent: 2005/0124639 (2005-06-01), Narendra et al.
patent: 2005/0131066 (2005-06-01), Niddam-Hildesheim et al.
patent: 2005/0159615 (2005-07-01), Lifshitz-Liron et al.
patent: 2005/0222415 (2005-10-01), Kumar et al.
patent: 2007/0037979 (2007-02-01), Niddam-Hildesheim et al.
patent: 2007/0123550 (2007-05-01), Niddam-Hildesheim et al.
patent: 2007/0167625 (2007-07-01), Balanov et al.
patent: 1 733 774 (2006-02-01), None
patent: 1807417 (2006-07-01), None
patent: 1 872 841 (2006-12-01), None
patent: 0 521 471 (1993-01-01), None
patent: 0 554 455 (1993-08-01), None
patent: 0 850 902 (1998-07-01), None
patent: 0 984 011 (2000-03-01), None
patent: 07 118233 (1995-05-01), None
patent: WO 00/17150 (2000-03-01), None
patent: WO 00/49014 (2000-08-01), None
patent: WO 01/60804 (2001-08-01), None
patent: WO 03/004455 (2003-01-01), None
patent: WO 03/016317 (2003-02-01), None
patent: WO 03/032995 (2003-04-01), None
patent: WO 03/087112 (2003-10-01), None
patent: WO 03/097614 (2003-11-01), None
patent: WO 2004/014872 (2004-02-01), None
patent: WO 2004/052867 (2004-06-01), None
patent: WO 2004/108691 (2004-12-01), None
patent: WO 2005/021511 (2005-03-01), None
patent: WO 2005/023778 (2005-03-01), None
patent: WO 2006/035277 (2006-04-01), None
patent: WO 2006/079611 (2006-08-01), None
patent: WO 2006/100689 (2006-09-01), None
patent: WO 2006/106526 (2006-10-01), None
patent: WO 2006/136407 (2006-12-01), None
patent: WO 2006/136408 (2006-12-01), None
patent: WO 2007/007119 (2007-01-01), None
Third Party Observations under Article 115 EPC in respect of European Patent Application No. EP06801964.5; Aug. 11, 2009.
Harwood, et al., “Experimental Organic Chemistry”, 1989, pp. 127-132.
Anelli, et al., “Fast and Selective Oxidation of Primary Alcohols to Aldehydes or to Carboxylic Acids and of Secondary Alcohols to Ketones Mediated by Oxoammonium Salts Under Two-Phase Conditions”,J. Org. Chem., 1987, pp. 2559-2562, vol. 52, No. 12.
Hull, et al., “Quantification of Rosuvastatin in Human Plasma by Automated Solid-Phase Extraction Using Tandem Mass Spectrometric Detection”,Journal of Chromatography B: Biomedical Sciences&Applications, 2002, pp. 219-228, vol. 772, No. 2.
Konoike, et al. “Practical Synthesis of Chiral Synthons for the Preparation of HMG-CoA Reductase Inhibitors”J. Org. Chem., vol. 59, 1994, pp. 7849-7854.
Lenz, et al., “Tetra-N-Propylammonium Perruthenate (TPAP)-Catalysed Oxidations of Alcohols Using Molecular Oxygen As a Co-Oxidant”,J. Chem. Soc., Perkin Trans. 1, 1997, 3291-3292.
Ley, et al.,Synthesis, 1994, 639-666.
Lipid Research Clinics Program, “The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease”,J.A.M.A., 1984, 351-74, vol. 251, No. 3.
Loubinoux, et al., “The Enantioselective Synthesis of Simplified Southern-Half Fragments of Soraphen A”,Tetrahedron, 1995, pp. 3549-3558, vol. 51, No. 12.
Ohrlein, et al., “Chemo-Enzymatic Approach to Statin Side-Chain Building Blocks”,Adv. Synth. Catal., 2003, pp. 713-715, vol. 345.
Scandinavian Simvastatin Survival Study Group, “Randomised Trial of Cholesterol Lowering in 4444 Patients With Coronary Heart Disease: The Scandinavian Survival Study (4s)”,The Lancet, 1994, pp. 1383-1389, vol. 344.
Snyder, et al.,Introduction to Modern Liquid Chromatography, 2nd ed., John Wiley & Sons: New York, 1979, pp. 549, 552, 571-572.
Strobel, et al.,Chemical Instrumentation: A Systematic Approach, 3rded., Wiley & Sons: New York, 1989, pp. 391-393, 879, 894, 922, 924-925, 953.
Szantay, et al., “Synthesis of Novel HMG-CoA Reductase Inhibitors, Naphthalene Analogs of Mevinolin”,Liebigs Ann. Chem., 1992, pp. 145-157.
Theisen, P.D. et al., “Improved procedure for preparation of optically active 3-hydroxyglutarate monoesters and 3-hydroxy-5-oxoalkanoic acids,”Journal of Organic Chemistry, vol. 53(10), 1988: 2374-2378.
Watanabe, Masamichi et al., “Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors,”Bioorganic&Medicinal Chemistry, 5(2), pp. 437-444, 1997.
Witztum, “Chapter 36: Drugs Used In The Treatment Of Hyperlipoproteinemias”,Goodman&Gilman's The Pharmacological Basis Of Therapeutics, 9thed., pp. 875-897, 1996.

Affiliated with

Also associated with

Rating

Crystalline rosuvastatin intermediate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline rosuvastatin intermediate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline rosuvastatin intermediate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2651222